Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Rhea-AI Summary

Biohaven closes underwritten public offering, raising approximately $258.7 million.

Positive

• Biohaven raised approximately $258.7 million in its underwritten public offering of common shares.

Negative

• None.

NEW HAVEN, Conn., Oct. 5, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 11,761,363 of its common shares, which includes the full exercise of the underwriters' option to purchase 1,534,090 additional common shares, at a public offering price of $22.00 per share. The gross proceeds from the offering were approximately $258.7 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.

J.P. Morgan, TD Cowen, Leerink Partners and Piper Sandler & Co. acted as the joint lead book-running managers of the offering, William Blair acted as a book-runner of the offering and BTIG acted as lead manager of the offering.

The offering was made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from the offices of the following: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com, Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at (833) 297-2926 or by email at Prospectus_ECM@cowen.com, Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com, and Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com.

The shares were issued pursuant to an effective shelf registration statement on Form S-3.  Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the expected use of proceeds therefrom, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including Biohaven's expectations related to the use of proceeds from the offering of its common shares. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
201-248-0741

Media Contact:

Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502

View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-301948542.html

SOURCE Biohaven Ltd.

FAQ

What was the public offering price per share?

The public offering price per share was $22.00.

How much did Biohaven raise in the offering?

Biohaven raised approximately $258.7 million in the offering.

What will Biohaven use the net proceeds for?

Biohaven intends to use the net proceeds for general corporate purposes.

Who were the lead book-running managers of the offering?

J.P. Morgan, TD Cowen, Leerink Partners, and Piper Sandler & Co. acted as the joint lead book-running managers of the offering.

How can I obtain copies of the prospectus?

Copies of the prospectus can be obtained from the offices of J.P. Morgan Securities LLC, Cowen and Company, LLC, Leerink Partners LLC, and Piper Sandler & Co.

Are there any forward-looking statements in the news release?

Yes, the news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.